1. European Medicines Agency. Notification of a referral under Article 107i of Directive 2001/83/EC [Internet]. 2013 Feb 28 [cited 2017 Sep 28]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Flupirtine-containing_medicines/Procedure_started/WC500139756.pdf
2. European Medicines Agency: EMA/404308/2013. Assessment report for flupirtine containing medicinal products [Internet]. 2013 Jun 24 [cited 2017 Sep 24]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Flupirtine-containing_medicines/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500146103.pdf
3. Teva Gmbh, Germany. Summary of Product Characteristics: Flupirtine [Internet]. 2015 [cited 2017 Sep 28]. Available from: http://mri.cts-mrp.eu/download/DE_H_3430_001_FinalSPC_2of2.pdf
4. The impact of risk minimization measures on compliance and prescribing practices of flupirtine in Germany
5. European Medicines Agency (EMA). Withdrawal of pain medicine flupirtine endorsed [Internet]. 2018 Mar 23 [cited 2018 Jun 18]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Flupirtine-31/Position_provided_by_CMDh/WC500248611.pdf